Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Unknown Primary × ipatasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 5 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasms, Unknown Primary 1 Mouth Neoplasms 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Gemcitabine 8 Carboplatin 8 Paclitaxel 6 Capecitabine 4 Irinotecan 3 Bevacizumab 3 pembrolizumab 2 atezolizumab 2 Peripheral Blood Stem Cell Transplantation 2 Oxaliplatin 2 Filgrastim 2 Erlotinib Hydrochloride 2 Cisplatin 2 CP protocol 2 tegafur-gimeracil-oteracil 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 entrectinib 1 cobimetinib 1 belinostat 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1 Vemurafenib 1 Transurethral Resection of Prostate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡